Literature DB >> 12181263

Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis.

Hagen Blaszyk1, Linan Wang, Wolfgang Dietmaier, Ferdinand Hofstädter, Lawrence J Burgart, John C Cheville, Arndt Hartmann.   

Abstract

Urothelial carcinoma of the renal pelvis and ureter may develop as a manifestation of the hereditary nonpolyposis colorectal cancer syndrome that is characterized by mutations in a number of DNA mismatch repair genes and detectable as microsatellite instability. In this study, we examined microsatellite instability and the clinicopathologic features of urothelial carcinoma of the renal pelvis (n = 61) and ureter (n = 53) from 114 consecutive patients surgically treated from 1985-1992. Clinical data were obtained through chart review. Matched normal and tumor DNA was extracted from paraffin-embedded tissue, and a panel of six microsatellite loci was analyzed. The male-female ratio was 2.8:1 with a median age of 70 years (range, 28 to 92 y). Microsatellite analysis was successful in 67 tumors, and 21 (31.3%) patients had tumors that exhibited microsatellite instability. Patients with microsatellite-unstable tumors were significantly more likely to have additional nonurologic cancers (P =.015) including colorectal carcinoma (P =.001) compared with patients with tumors that did not exhibit microsatellite instability. In addition, patients with microsatellite-unstable tumors showed more colorectal cancers in their family (P =.026) and were more likely to have higher grade urothelial carcinoma of the upper tract (P =.028). Grade and stage, but not microsatellite status, were the strongest predictors of cancer-specific survival. This study found the highest frequency of microsatellite instability in upper urothelial tract carcinomas reported to date and highlights upper tract urothelial carcinoma as a marker of the hereditary nonpolyposis colorectal cancer syndrome in some patients. These findings reinforce the importance of obtaining cancer histories in patients with upper tract urothelial carcinoma to subsequently identify individuals with the hereditary nonpolyposis colorectal cancer syndrome and at-risk relatives for surveillance and management programs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181263     DOI: 10.1097/01.MP.0000024263.25043.0C

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Spontaneously arising concurrent ileocaecal adenocarcinoma and renal pelvis transitional cell carcinoma in a rhesus macaque (Macaca mulatta).

Authors:  S Gumber; J S Wood; A C Jones; E Strobert
Journal:  J Comp Pathol       Date:  2013-09-06       Impact factor: 1.311

2.  Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis.

Authors:  Laleh Ehsani; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2014-05-30

Review 3.  Surveillance for urinary tract cancer in Lynch syndrome.

Authors:  Inge Thomsen Bernstein; Torben Myrhøj
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

4.  Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome.

Authors:  Holly L Harper; Jesse K McKenney; Brandie Heald; Andrew Stephenson; Steven C Campbell; Thomas Plesec; Cristina Magi-Galluzzi
Journal:  Mod Pathol       Date:  2016-10-07       Impact factor: 7.842

5.  A clinical study on surgical causes of Hematuria.

Authors:  Kewithinwangbo Newme; Ranendra Hajong; Ratna Kanta Bhuyan
Journal:  J Family Med Prim Care       Date:  2021-01-30

Review 6.  MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?

Authors:  Alessandra Cinque; Anna Capasso; Riccardo Vago; Matteo Floris; Michael W Lee; Roberto Minnei; Francesco Trevisani
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

7.  Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma.

Authors:  Kajsa M Ericson; Anna P Isinger; Björn L Isfoss; Mef C Nilbert
Journal:  BMC Cancer       Date:  2005-03-01       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.